Scientific Reports (Jan 2022)

Relevance of gene mutations and methylation to the growth of pancreatic intraductal papillary mucinous neoplasms based on pyrosequencing

  • Go Asano,
  • Katsuyuki Miyabe,
  • Hiroyuki Kato,
  • Michihiro Yoshida,
  • Takeshi Sawada,
  • Yasuyuki Okamoto,
  • Hidenori Sahashi,
  • Naoki Atsuta,
  • Kenta Kachi,
  • Akihisa Kato,
  • Naruomi Jinno,
  • Makoto Natsume,
  • Yasuki Hori,
  • Itaru Naitoh,
  • Kazuki Hayashi,
  • Yoichi Matsuo,
  • Satoru Takahashi,
  • Hiromu Suzuki,
  • Hiromi Kataoka

DOI
https://doi.org/10.1038/s41598-021-04335-z
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 11

Abstract

Read online

Abstract We aimed to assess some of the potential genetic pathways for cancer development from non-malignant intraductal papillary mucinous neoplasm (IPMN) by evaluating genetic mutations and methylation. In total, 46 dissected regions in 33 IPMN cases were analyzed and compared between malignant-potential and benign cases, or between malignant-potential and benign tissue dissected regions including low-grade IPMN dissected regions accompanied by malignant-potential regions. Several gene mutations, gene methylations, and proteins were assessed by pyrosequencing and immunohistochemical analysis. RASSF1A methylation was more frequent in malignant-potential dissected regions (p = 0.0329). LINE-1 methylation was inversely correlated with GNAS mutation (r = − 0.3739, p = 0.0105). In cases with malignant-potential dissected regions, GNAS mutation was associated with less frequent perivascular invasion (p = 0.0128), perineural invasion (p = 0.0377), and lymph node metastasis (p = 0.0377) but significantly longer overall survival, compared to malignant-potential cases without GNAS mutation (p = 0.0419). The presence of concordant KRAS and GNAS mutations in the malignant-potential and benign dissected regions were more frequent among branch-duct IPMN cases than among the other types (p = 0.0319). Methylation of RASSF1A, CDKN2A, and LINE-1 and GNAS mutation may be relevant to cancer development, IPMN subtypes, and cancer prognosis.